Evidence map›Paper›PMID 24767177›Full record

ArticleRetrovirology2014

Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.

Nancy P Y Chung, Katie Matthews, Helen J Kim, Thomas J Ketas, Michael Golabek, Kevin de Los Reyes, Jacob Korzun, Anila Yasmeen, Rogier W Sanders, Per Johan Klasse and 5 more

Abstract read
In one paragraph

Article in Retrovirology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. A reversed phase HPLC method for the quantification of HIV gp145 glycoprotein levels from cell culture supernatants.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2021
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nancy P Y Chung
Katie Matthews
Helen J Kim
Thomas J Ketas
Michael Golabek
Kevin de Los Reyes
Jacob Korzun
Anila Yasmeen
Rogier W Sanders
Per Johan Klasse
Ian A Wilson
Andrew B Ward
Andre J Marozsan
John P MooreDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA. jpm2003@med.cornell.edu.
Albert Cupo

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Trimer Production and Immunogenicity TestingP01AI082362 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2009 to 2014
$16.0M
NIAID NIH HHS P01 AI082362NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

backgroundRecombinant soluble, cleaved HIV-1 envelope glycoprotein SOSIP.664 gp140 trimers based on the subtype A BG505 sequence are being studied structurally and tested as immunogens in animals. For these trimers to become a vaccine candidate for human trials, they would need to be made in appropriate amounts at an acceptable quality. Accomplishing such tasks by transient transfection is likely to be challenging. The traditional way to express recombinant proteins in large amounts is via a permanent cell line, usually of mammalian origin. Making cell lines that produce BG505 SOSIP.664 trimers requires the co-expression of the Furin protease to ensure that the cleavage site between the gp120 and gp41 subunits is fully utilized.

resultsWe designed a vector capable of expressing Env and Furin, and used it to create Stable 293 T and CHO Flp-In™ cell lines through site-specific recombination. Both lines produce high quality, cleaved trimers at yields of up to 12-15 mg per 1 × 109 cells. Trimer expression at such levels was maintained for up to 30 days (10 passages) after initial seeding and was consistently superior to what could be achieved by transient transfection. Electron microscopy studies confirm that the purified trimers have the same native-like appearance as those derived by transient transfection and used to generate high-resolution structures. They also have appropriate antigenic properties, including the presentation of the quaternary epitope for the broadly neutralizing antibody PGT145.

conclusionsThe BG505 SOSIP.664 trimer-expressing cell lines yield proteins of an appropriate quality for structural studies and animal immunogenicity experiments. The methodology is suitable for making similar lines under Good Manufacturing Practice conditions, to produce trimers for human clinical trials. Moreover, any env gene can be incorporated into this vector system, allowing the manufacture of SOSIP trimers from multiple genotypes, either by transient transfection or from stable cell lines.

Indexed as

AnimalsAntibodies, NeutralizingAntigens, ViralCell LineCHO CellsCricetulusenv Gene Products, Human Immunodeficiency VirusFurinGene ExpressionGlycoproteinsHEK293 CellsHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41HumansAntibodies, NeutralizingAntigens, Viralenv Gene Products, Human Immunodeficiency VirusFurinGlycoproteinsgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41Recombinant ProteinsVaccines

Identifiers

PMID24767177
PMCPMC4032163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.